NeoPath buys CompuCyte's Pathfinder system
This article was originally published in Clinica
Executive Summary
NeoPath has paid $5 million in cash and stock for CompuCyte's Pathfinder system. The product is used to improve quality assurance in the clinical cytology laboratory by computerising cytotechnologists' microscopes. This can be used to help eliminate screening errors and facilitate critical cell relocation in applications such as Pap smear screening for the early detection of cervical cancer.